About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
A
55 y/o Diagnosed With T3NO TNBC / 42 y/o With cT2N+ Grade IlTNBC, Received Neoadjuvant Taxol/Carbo/Pembro
By
KU 2019 Post San Antonio Breast Cancer Review
FEATURING
Allison Kurian
,
Qamar Khan
,
Priyanka Sharma
,
Virginia Kaklamani
,
Terry Mamounas
,
William Gradishar
March 12, 2020
0 Comments
Login to view comments.
Click here to Login
Featured Video
18:15
Novartis Oncology
CDK4/6 Inhibitor in Postmenopausal Patients With HR+/HER2- mBC: Anal…
Feat.
G. Hortobagyi
Featured Video
17:04
Novartis Oncology
Discussion on Overall Survival Data Across 3 Phase III Trials in HR+…
Feat.
G. Hortobagyi
Related Content
AUTOPLAY
ON
16:44
Heather McArthur
Modern Immune Therapy Strategies for Triple-Negative Breast Cancer
07:43
Dana-Farber Cancer Institute
Study of Abemaciclib for Patients with RB-Positive, Triple Negative …
Feat.
S. Goel
10:12
Holy Cross 9th Annual Winter Oncology Symposium
Emerging Targets in HER-2 Negative, TNBC and HER-3 Positive Breast C…
Feat.
M. Abu-Khalaf
10:53
Baltic and Eurasia Masterclass in Clinical Oncology
Neoadjuvant Systemic Therapy for HER2 + Early Breast Cancer - Review…
Feat.
A. Česas
13:21
12th ESO-EONS Masterclass in Oncology Nursing
Neo-Adjuvant Therapy: For Who is Indicated? (Nurses)
Feat.
O. Pagani
07:58
12th ESO-EONS Masterclass in Oncology Nursing
Triple Negative Disease: Adjuvant Therapy, Hormone Receptor + Diseas…
Feat.
O. Pagani
13:36
Baltic and Eurasia Masterclass in Clinical Oncology
Systemic Treatment of TNBC: Staging, BRCAness, Chemotherapy Prognost…
Feat.
E. Kharchenko
10:06
5th Annual Cleveland Breast Cancer Summit: Collaborating For A Cure
NCCN Guidelines Update for TNBC and HER2 Breast Cancer: Immunotherap…
Feat.
J. Abraham,
W. Gradishar
08:27
5th Annual Cleveland Breast Cancer Summit: Collaborating For A Cure
Therapeutic Options for Systemic Treatment of TNBC & New Data on…
Feat.
D. Hicks
15:23
5th Annual Cleveland Breast Cancer Summit: Collaborating For A Cure
Q&A on Clinical Data Behind Changing the Guidelines, Her2+ Testi…
Feat.
D. Hicks
18:38
Peter Schmid
Immunotherapy in Metastatic Triple Negative Breast Cancer: IMpassion…
07:40
Dana-Farber Cancer Institute
Study of Carboplatin plus Nivolumab in Metastatic Triple-Negative Br…
Feat.
S. Tolaney
33:18
Elisa Krill-Jackson
Advances In Treatment of Early Breast Cancer: Tailoring Therapy Usin…
07:58
Elisa Krill-Jackson
Immunotherapy for TNBC & PARP Inhibitors for BRCA Mutations
16:09
Ashley Mathews
The Breast Tumor Microenvironment: TILs as Therapeutic Target and Pr…
05:52
Ashley Mathews
PD-L1 Testing in Breast Cancer: What Makes a Breast Cancer Patient E…
14:11
UNC Lineberger Comprehensive Cancer Center
UNC's 2019 ASCO Update on Margetuximab + Chemo vs Trastuzumab v…
Feat.
E. Ray
16:01
5th Annual Cleveland Breast Cancer Summit: Collaborating For A Cure
Evolving Strategies for Enhancing the Impact of Immunotherapy in TNB…
Feat.
H. Rugo
14:34
5th Annual Cleveland Breast Cancer Summit: Collaborating For A Cure
Enhancing the Impact of IO in Metastatic / Locally Advanced TNBC: At…
Feat.
H. Rugo
05:41
5th Annual Cleveland Breast Cancer Summit: Collaborating For A Cure
Enhancing the Impact of Immunotherapy in TNBC: IO Therapy Options in…
Feat.
H. Rugo